Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		A phase I/II Evaluation of Vaccination with Type-1 Dendritic Cells Pulsed With Multiple Peptides In the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas

		Keywords:		Dendritic Cell Immunotherapy

		Phase:		Phase 1

		Treatment ID#s:		VT1626 UPCI 05-115

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Newly Diagnosed: N Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Patients must have a recurrent glioblastoma or anaplastic glioma that is histologically confirmed either by the previous biopsy or resection, or at the time of re-operation. Patients must have received prior external beam radiotherapy and/or chemotherapy unless patients refused the options. Patients must be HLA-A2 positive, which can be determined in our screening process.

		Last Updated:		03/02/2008

		Tumor Types:		Anaplastic Astrocytoma Glioblastoma Multiforme Gliosarcoma Mixed Glioma Oligodendroglioma High Grade


		Comments:		This is a novel glioma-vaccine trial that incorporates the following recent laboratory discoveries from our own laboratory: 1) Use of novel alpha DC1 – these DCs are at least 40 times more potent than conventional DCs in their ability to induce anti-tumor T-cell response 2) Use of novel synthetic peptides designed from 4 glioma associated antigens – as all cancers are heterogeneous in their antigen expression profile, targeting single antigens in vaccines may result in outgrowth of tumor cells that have lost the expression of the targeted antigen. In our trial, by targeting 4 antigens, we aim to induce effective immune response against antigens that are expressed in most glioma tissues and cells.

		Treatment Type:		Immunological, Biological or Targeted Therapy.

		Contact:		U. Of Pittsburgh Cancer Institute/Hillman Cancer Center Hideho Okada, M.D., Ph.D. Associate Professor G12a. Hillman Cancer Center 5117 Centre Avenue Pittsburgh, PA 15213 Phone:(412)623-1111 Fax: (412)623-4747 Click here to send an email Website: http://www.upci.upmc.edu/research/clinical/brain/leader.html

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By